Up­dat­ed: Eli Lil­ly's tirzepatide breaks in­to obe­si­ty mar­ket with FDA ap­proval

Eli Lil­ly’s tirzepatide is of­fi­cial­ly en­ter­ing the mar­ket for chron­ic weight man­age­ment.

The drug­mak­er said Wednes­day that the GIP/GLP-1 re­cep­tor ag­o­nist, which is known as Moun­jaro for type 2 di­a­betes, can now be mar­ket­ed as Zep­bound for weight man­age­ment in adults with obe­si­ty or over­weight with “weight-re­lat­ed” health con­di­tions.

It is set to be avail­able in the US by the end of the year, in six dos­es with a list price of $1,059.87. Ac­cord­ing to Lil­ly, that price is about 20% low­er than the list price of a 2.4 mg dose of We­govy, No­vo Nordisk’s GLP-1 for weight loss. The list price for We­govy is $1,349.02 per pack­age, ac­cord­ing to No­vo’s web­site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER